ZA991315B - Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia. - Google Patents

Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.

Info

Publication number
ZA991315B
ZA991315B ZA9901315A ZA991315A ZA991315B ZA 991315 B ZA991315 B ZA 991315B ZA 9901315 A ZA9901315 A ZA 9901315A ZA 991315 A ZA991315 A ZA 991315A ZA 991315 B ZA991315 B ZA 991315B
Authority
ZA
South Africa
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
novel substituted
substituted pyridino
Prior art date
Application number
ZA9901315A
Other languages
English (en)
Inventor
Gee-Hong Kuo
William V Murray
Catherine P Prouty
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ZA991315B publication Critical patent/ZA991315B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA9901315A 1998-02-20 1999-02-18 Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia. ZA991315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7532198P 1998-02-20 1998-02-20

Publications (1)

Publication Number Publication Date
ZA991315B true ZA991315B (en) 2000-11-20

Family

ID=22124955

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901315A ZA991315B (en) 1998-02-20 1999-02-18 Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.

Country Status (23)

Country Link
US (1) US6218396B1 (enExample)
EP (1) EP1054868B1 (enExample)
JP (1) JP2002503724A (enExample)
KR (1) KR100591028B1 (enExample)
CN (1) CN1121390C (enExample)
AR (1) AR014626A1 (enExample)
AT (1) ATE250580T1 (enExample)
AU (1) AU766398B2 (enExample)
BR (1) BR9909647A (enExample)
CZ (1) CZ294136B6 (enExample)
DE (1) DE69911582T2 (enExample)
DK (1) DK1054868T3 (enExample)
ES (1) ES2209468T3 (enExample)
HU (1) HUP0100781A3 (enExample)
IL (2) IL137954A0 (enExample)
NO (1) NO317103B1 (enExample)
NZ (1) NZ506462A (enExample)
PL (1) PL342339A1 (enExample)
PT (1) PT1054868E (enExample)
TR (1) TR200003220T2 (enExample)
TW (1) TW565555B (enExample)
WO (1) WO1999042448A1 (enExample)
ZA (1) ZA991315B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD545208S1 (en) 2006-09-27 2007-06-26 001 Corporation Perfume bottle and cap

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269807C (zh) * 1997-05-12 2006-08-16 奥索-麦克尼尔药品公司 可用于治疗良性前列腺肥大的芳基取代哌嗪
ES2282279T3 (es) 2000-08-08 2007-10-16 Ortho-Mcneil Pharmaceutical, Inc. No-imidazol ariloxipiperidina como ligandos del receptor h3.
JP3878178B2 (ja) * 2001-12-28 2007-02-07 武田薬品工業株式会社 排尿障害予防治療剤
EP2077262A4 (en) * 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
MX2010011652A (es) * 2008-04-23 2010-12-06 Takeda Pharmaceutical Derivados de iminopiridina y uso de los mismos.
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CN103980195A (zh) * 2014-04-28 2014-08-13 广州医科大学 酰胺类苯基哌嗪衍生物及其盐与在制备治疗良性前列腺增生症药物中的应用
CN108530391B (zh) * 2018-05-17 2022-05-17 袁牧 一种酰胺类芳基哌嗪衍生物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
US5688795A (en) * 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
AU8130298A (en) * 1997-07-15 1999-02-10 Sankyo Company Limited Piperazine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD545208S1 (en) 2006-09-27 2007-06-26 001 Corporation Perfume bottle and cap

Also Published As

Publication number Publication date
JP2002503724A (ja) 2002-02-05
CN1121390C (zh) 2003-09-17
EP1054868A1 (en) 2000-11-29
AU766398B2 (en) 2003-10-16
IL137954A0 (en) 2001-10-31
DE69911582D1 (de) 2003-10-30
US6218396B1 (en) 2001-04-17
CZ20003044A3 (cs) 2001-04-11
NO20004141L (no) 2000-10-19
HUP0100781A2 (hu) 2001-08-28
AR014626A1 (es) 2001-03-28
TW565555B (en) 2003-12-11
WO1999042448A1 (en) 1999-08-26
TR200003220T2 (tr) 2001-04-20
HK1030776A1 (en) 2001-05-18
CN1291188A (zh) 2001-04-11
IL137954A (en) 2007-06-03
DK1054868T3 (da) 2003-12-22
KR20010041115A (ko) 2001-05-15
NZ506462A (en) 2003-07-25
CZ294136B6 (cs) 2004-10-13
ES2209468T3 (es) 2004-06-16
BR9909647A (pt) 2000-11-21
ATE250580T1 (de) 2003-10-15
NO20004141D0 (no) 2000-08-18
AU3302599A (en) 1999-09-06
KR100591028B1 (ko) 2006-06-22
PL342339A1 (en) 2001-06-04
EP1054868B1 (en) 2003-09-24
HUP0100781A3 (en) 2002-12-28
DE69911582T2 (de) 2005-09-15
PT1054868E (pt) 2004-01-30
NO317103B1 (no) 2004-08-09

Similar Documents

Publication Publication Date Title
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
IL141235A0 (en) Combined use of an alpha-adrenoceptor antagonist and amuscarinic antagonist in the treatment of benign prostatic hyperplasi
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
IL120302A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
ZA983968B (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia.
ZA200005372B (en) Water-softening and detergent compositions.
ZA981781B (en) The use of levobupivacaine in treating migraine
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
MXPA01011720A (es) 3-piridil-4-arilpirroles sustituidos, y metodos terapeuticos y profilacticos relacionados.
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
EP0633781A4 (en) COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY.
BG104914A (en) Paroxetine maleate
AU2002232403A1 (en) Del-1 and benign prostatic hyperplasia
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
ZA200104744B (en) Compositions comprising 1,1,1,3, 3-pentafluorobutane and use of said compositions.
ZA200202930B (en) Methods and compositions utilizing quinazolinones.